ScholarLens Back to search
2012•Kidney InternationalOpen access

Should mycophenolate mofetil replace cyclophosphamide as first-line therapy for severe lupus nephritis?

Jonathan J. Hogan, Michael H. Schwenk, Jai Radhakrishnan

Open full text 17 citations

Abstract

This record does not include an abstract. Use the full-text link above if available.

Open-access reader

About this research paper

What this paper is about

An abstract is not available in the OpenAlex record for this paper.

Why it matters

OpenAlex reports 17 citations for this work. Citation counts describe recorded attention and do not establish research quality.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Key concepts: Mycophenolate, Lupus nephritis, Medicine, Cyclophosphamide, Dermatology, Mycophenolic acid, First line therapy, Nephritis

Related papers

Related paper 1Related paper 2Related paper 3
Back to paper searchBrowse research topicsOriginal source
Should mycophenolate mofetil replace cyclophosphamide as first-line therapy for severe lupus nephritis? — Research Paper | ScholarLens